Key result
Delayed rapamycin reverses cardiac allograft vasculopathy, whereas delayed cyclosporine shows no effect.
Why the study?
Chronic graft vascular disease in cardiac allografts is a slowly evolving vasculopathy unresponsive to conventional immunosuppression, requiring evaluation of treatment effects.
Does delayed rapamycin treatment reverse chronic graft vascular disease in a rodent cardiac allograft model compared to cyclosporine?
Does delayed rapamycin treatment reverse chronic graft vascular disease in a rodent cardiac allograft model compared to cyclosporine?
Delayed rapamycin treatment reverses established chronic graft vascular disease in a rodent cardiac allograft model, whereas cyclosporine does not.
Answers are grounded in this paper and cite their sources.
Rodent CGVD models and Rapa/CSA effects require clinical validation; leaves open human cardiac allograft vasculopathy relevance.
BACKGROUND: Chronic graft vascular disease (CGVD) in cardiac allografts has been defined as a slowly evolving vasculopathy unresponsive to conventional immunosuppression. We compared 4 rodent models of CGVD to evaluate the reproducibility of CGVD in heart allografts. Rapamycin (Rapa) and cyclosporine (CSA) were then used to treat CGVD. METHODS AND RESULTS: Hearts were harvested and placed heterotopically into allogenic recipients. CGVD scores of PVG allografts from ACI recipients treated with CSA on days 1 through 10 were significantly elevated on day 90 (n=16) compared with other models (immunosuppression used): (1) Lewis to F344 recipients (CSA), (2) Brown Norway to Lewis (FK506), and (3) DA to Wistar-Firth (methylprednisolone, azathioprine, CSA). Although delayed (day 60 to 90) CSA treatment had no effect (n=6), delayed Rapa (3 mg. kg-1. d-1 IP) reversed CGVD in PVG grafts (0.22+/-0.19 on day 90, n=6). ACI isografts showed no evidence of CGVD (n=6) at day 90. Immunohistochemistry of PVG grafts revealed perivascular infiltrates consisting of CD4(+) T cells and limited numbers of macrophages persisting up to day 90. Flow cytometry demonstrated increased levels of anti-donor antibody at day 90, which was significantly inhibited by Rapa treatment. CONCLUSIONS: PVG grafts developed a significant increase in CGVD without evidence of ongoing myocardial rejection. This CGVD appeared to be mediated by both cellular and humoral mechanisms, given CD4(+) perivascular infiltrates and increased levels of anti-donor antibody. The anti-CGVD effectiveness of Rapa during a period in which there was little myocardial cellular infiltrate supports a novel mechanism of effect such as smooth muscle or B-cell inhibition.
No takes yet. Share an insight, caveat, or question.
Poston et al. (1999) studied Chronic graft vascular disease (CGVD) in cardiac allografts (n=34). Rapamycin vs. Cyclosporine was evaluated on CGVD scores at day 90. Delayed rapamycin treatment reversed chronic graft vascular disease in PVG cardiac allografts by day 90, whereas delayed cyclosporine had no effect.
Synapse has enriched 10 related papers. Consider them for comparative context: